地诺单抗中国上市价格

In May 2019, it was approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or that may result in severe functional disability after surgical resection, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and a body weight of ≥45 kg). 

Denosumab is the first approved monoclonal antibody that specifically targets RANK ligand. Its launch has caused quite a stir in my country, and many patients are also very concerned about the price of denosumab. So what will be the price of denosumab after it is launched in China?

Since denosumab is conditionally approved for marketing in my country and has been on the market for a relatively short time, its domestic price has not yet been collected. However, according to the past experience of anti-tumor drugs being launched in my country, the price of denosumab original drugs is usually very high. No matter how good the therapeutic effect of a drug is, if the price is too high, it will be out of reach for patients with heavy financial burdens. Long-term use will cause huge financial pressure on them. So besides China, where else can denosumab be obtained? What's the price?

Medical Travel has learned that denosumab produced by Amgen of the United States and marketed in Turkey is relatively cheap. The specification is 125mg/1ml tube/box, and the equivalent price in RMB is about $3,000. Patients in need can further contact the medical companion service to learn more about denosumab. 

Giant cell tumor of bone is an extremely rare and rapidly progressing primary bone tumor rich in human nuclear factor activator ligand (RANKL), manifesting as eccentric bony lesions in the metaphysis and epiphysis of long bones or the spine and sacrum. And compared with European and American populations, it is more common in China, accounting for about 20% of all primary bone tumors. It has significantly controlled the progression of the disease and improved the quality of life of patients. The approval of denosumab in China will bring new treatment options to domestic patients.